Health Assurance Acquisition Corp.
HAAC
NASDAQ Capital Market10.05
USD
- -
- -
CIK
0001824013
ISIN
US42226W1099
CUSIP
42226W109
Return %
Stock
S&P500
1Y
2.55
26.53
3Y
-10.67
76.60
5Y
-10.67
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 20 University Road Cambridge MA United States of America 02138
- IPO Date
- Jan 14, 2021
- CIK
- 0001824013
- Website
- healthassuranceacqcorp.com
- Similar Companies
- Business
- Health Assurance Acquisition Corp. (HAAC) operates as a blank check company whose primary business is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting healthcare companies leveraging technology to create consumer-centric, data-driven solutions. Incorporated in 2020 and headquartered in Cambridge, Massachusetts, the company previously operated as Healthcare Assurance Acquisition Corp. before changing its name in October 2020; it conducted an initial public offering in November 2020 raising approximately $500 million to pursue such transactions, particularly those fostering a "health assurance" system aimed at improving outcomes, reducing costs, and enhancing equitable access in healthcare. HAAC does not currently engage in significant operations or generate revenues, focusing instead on identifying suitable targets in the healthcare technology sector, with sponsorship from General Catalyst and a leadership team experienced at the intersection of healthcare, technology, and venture investment. In October 2022, the company announced it would redeem all outstanding public shares and cease operations after failing to complete an initial business combination within the required 24-month period following its IPO, resulting in the delisting of its securities from Nasdaq and the expiration of its warrants; as of late 2025, its securities continue to trade over-the-counter at around $10.05 per share with no reported merger activity or further developments.